Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Gram-Negative Infections | Current Treatment: Physician Insights | US | 2019

Login to access report north_east
Contact sales account_box

Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) market. Most inpatients are successfully treated empirically with such agents, making it difficult for branded products like Merck & Co.’s Zerbaxa, Allergan’s Avycaz, Melinta’s Vabomere and Baxdela, Achaogen’s Zemdri, Tetraphase’s Xerava, or Paratek’s Nuzyra to gain uptake in earlier lines of therapy. However, rising antimicrobial resistance rates have created the need for safer products to effectively treat drug-resistant GNIs, and our primary market research shows that activity against key drug-resistant pathogens is an important driver of brand use in this market. Furthermore, hospital-based ID specialists report shifts in how they treat GNIs in response to the growing drug resistance.

QUESTIONS ANSWERED

  • What are the most prescribed first-, second-, and third-line therapies for inpatients with urinary tract infections, nosocomial pneumonia, or complicated intra-abdominal infections?
  • How are physicians approaching the treatment of infections caused by drug resistant pathogens?
  • Which clinical and nonclinical factors drive, and prevent, the prescribing of branded agents such as Zerbaxa, Avycaz, Vabomere, Zemdri, and Xerava?
  •  What will be the impact of the recent approval of Vabomere, Zemdri, Xerava, and other new agents? What will drive use of these therapies, and in which populations will they be used? Which current agents will be most affected?

PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use, so you can create specific messaging around these treatment dynamics in order to more effectively
increase or defend your market position.

GEOGRAPHIES: United States

PRIMARY RESEARCH: Survey of 100 U.S. hospital based, infectious disease and critical care specialists

KEY DRUGS COVERED: Avycaz, Zerbaxa, Vabomere, Zemdri, Xerava, Nuzyra, Baxdela, and other key GNI drugs

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Amyotrophic Lateral Sclerosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Amyotrophic lateral sclerosis (ALS) is a disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of the muscles and loss of…
north_east
Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, patients must…
north_east
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the…
north_east
Report
Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by…
north_east
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east